PDF(Sci-hub)
Abstract：
The European Association of Urology (EAU) panel on Non-muscle-invasive Bladder Cancer (NMIBC) released an updated version of the guidelines on Non-muscle-invasive Bladder Cancer.
To present the 2016 EAU guidelines on NMIBC.
A broad and comprehensive scoping exercise covering all areas of the NMIBC guidelines published between April 1, 2014, and May 31, 2015, was performed. Databases covered by the search included Medline, Embase, and the Cochrane Libraries. Previous guidelines were updated, and levels of evidence and grades of recommendation were assigned.
Tumours staged as TaT1 or carcinoma in situ (CIS) are grouped as NMIBC. Diagnosis depends on cystoscopy and histologic evaluation of the tissue obtained by transurethral resection of the bladder (TURB) in papillary tumours or by multiple bladder biopsies in CIS. In papillary lesions, a complete TURB is essential for the patient\'s prognosis. If the initial resection is incomplete, there is no muscle in the specimen, or a high-grade or T1 tumour is detected, a second TURB should be performed within 2-6 wk. The risks of both recurrence and progression may be estimated for individual patients using the European Organisation for Research and Treatment of Cancer (EORTC) scoring system and risk tables. The stratification of patients into low-, intermediate-, and high-risk groups is pivotal to recommending adjuvant treatment. For patients with a low-risk tumour and intermediate-risk patients at a lower risk of recurrence, one immediate instillation of chemotherapy is recommended. Patients with an intermediate-risk tumour should receive 1 yr of full-dose bacillus Calmette-Guérin (BCG) intravesical immunotherapy or instillations of chemotherapy for a maximum of 1 yr. In patients with high-risk tumours, full-dose intravesical BCG for 1-3 yr is indicated. In patients at highest risk of tumour progression, immediate radical cystectomy (RC) should be considered. RC is recommended in BCG-refractory tumours. The long version of the guidelines is available at the EAU Web site (www.uroweb.org/guidelines).
These abridged EAU guidelines present updated information on the diagnosis and treatment of NMIBC for incorporation into clinical practice.
The European Association of Urology has released updated guidelines on Non-muscle-invasive Bladder Cancer (NMIBC). Stratification of patients into low-, intermediate-, and high-risk groups is essential for decisions about adjuvant intravesical instillations. Risk tables can be used to estimate risks of recurrence and progression. Radical cystectomy should be considered only in case of failure of instillations or in NMIBC with the highest risk of progression.
To present the 2016 EAU guidelines on NMIBC.
A broad and comprehensive scoping exercise covering all areas of the NMIBC guidelines published between April 1, 2014, and May 31, 2015, was performed. Databases covered by the search included Medline, Embase, and the Cochrane Libraries. Previous guidelines were updated, and levels of evidence and grades of recommendation were assigned.
Tumours staged as TaT1 or carcinoma in situ (CIS) are grouped as NMIBC. Diagnosis depends on cystoscopy and histologic evaluation of the tissue obtained by transurethral resection of the bladder (TURB) in papillary tumours or by multiple bladder biopsies in CIS. In papillary lesions, a complete TURB is essential for the patient\'s prognosis. If the initial resection is incomplete, there is no muscle in the specimen, or a high-grade or T1 tumour is detected, a second TURB should be performed within 2-6 wk. The risks of both recurrence and progression may be estimated for individual patients using the European Organisation for Research and Treatment of Cancer (EORTC) scoring system and risk tables. The stratification of patients into low-, intermediate-, and high-risk groups is pivotal to recommending adjuvant treatment. For patients with a low-risk tumour and intermediate-risk patients at a lower risk of recurrence, one immediate instillation of chemotherapy is recommended. Patients with an intermediate-risk tumour should receive 1 yr of full-dose bacillus Calmette-Guérin (BCG) intravesical immunotherapy or instillations of chemotherapy for a maximum of 1 yr. In patients with high-risk tumours, full-dose intravesical BCG for 1-3 yr is indicated. In patients at highest risk of tumour progression, immediate radical cystectomy (RC) should be considered. RC is recommended in BCG-refractory tumours. The long version of the guidelines is available at the EAU Web site (www.uroweb.org/guidelines).
These abridged EAU guidelines present updated information on the diagnosis and treatment of NMIBC for incorporation into clinical practice.
The European Association of Urology has released updated guidelines on Non-muscle-invasive Bladder Cancer (NMIBC). Stratification of patients into low-, intermediate-, and high-risk groups is essential for decisions about adjuvant intravesical instillations. Risk tables can be used to estimate risks of recurrence and progression. Radical cystectomy should be considered only in case of failure of instillations or in NMIBC with the highest risk of progression.
摘要：
欧洲泌尿外科协会（EAU）非肌肉浸润性膀胱癌（NMIBC）小组发布了非肌肉浸润性膀胱癌指南的更新版本。
介绍关于NMIBC的2016年EAU指南。
在2014年4月1日至2015年5月31日期间发布的NMIBC指南的所有领域进行了广泛而全面的范围界定。搜索涵盖的数据库包括Medline，Embase,和Cochrane图书馆.以前的指南已更新，并分配了证据水平和推荐等级.
分期为TaT1或原位癌(CIS)的肿瘤被分组为NMIBC。诊断取决于膀胱镜检查和对乳头状肿瘤中经尿道膀胱电切术（TURB）或CI中多次膀胱活检获得的组织的组织学评估。在乳头状病变中，完整的TURB对患者的预后至关重要。如果最初的切除不完整，标本里没有肌肉,或检测到高级别或T1肿瘤，应在2-6周内进行第二次TURB。可以使用欧洲癌症研究和治疗组织(EORTC)评分系统和风险表估计个体患者的复发和进展风险。将患者分层为低，中介-，高危人群是推荐辅助治疗的关键。对于低风险肿瘤患者和复发风险较低的中危患者，建议立即滴注化疗。患有中危肿瘤的患者应接受1年的全剂量卡介苗（BCG）膀胱内免疫治疗或滴注化疗，最长为1年。在高危肿瘤患者中，显示1-3年的全剂量膀胱内BCG。在肿瘤进展风险最高的患者中，应考虑立即行根治性膀胱切除术（RC）。RC被推荐用于BCG难治性肿瘤。指南的长版可在EAU网站上获得（www。uroweb.org/guidelines)。
这些简化的EAU指南提供了有关NMIBC的诊断和治疗的最新信息，以纳入临床实践。
欧洲泌尿外科协会发布了关于非肌肉浸润性膀胱癌（NMIBC）的最新指南。将患者分层为低，中介-，高危人群对于辅助膀胱灌注的决定至关重要.风险表可用于估计复发和进展的风险。只有在滴注失败或进展风险最高的NMIBC中，才应考虑根治性膀胱切除术。
介绍关于NMIBC的2016年EAU指南。
在2014年4月1日至2015年5月31日期间发布的NMIBC指南的所有领域进行了广泛而全面的范围界定。搜索涵盖的数据库包括Medline，Embase,和Cochrane图书馆.以前的指南已更新，并分配了证据水平和推荐等级.
分期为TaT1或原位癌(CIS)的肿瘤被分组为NMIBC。诊断取决于膀胱镜检查和对乳头状肿瘤中经尿道膀胱电切术（TURB）或CI中多次膀胱活检获得的组织的组织学评估。在乳头状病变中，完整的TURB对患者的预后至关重要。如果最初的切除不完整，标本里没有肌肉,或检测到高级别或T1肿瘤，应在2-6周内进行第二次TURB。可以使用欧洲癌症研究和治疗组织(EORTC)评分系统和风险表估计个体患者的复发和进展风险。将患者分层为低，中介-，高危人群是推荐辅助治疗的关键。对于低风险肿瘤患者和复发风险较低的中危患者，建议立即滴注化疗。患有中危肿瘤的患者应接受1年的全剂量卡介苗（BCG）膀胱内免疫治疗或滴注化疗，最长为1年。在高危肿瘤患者中，显示1-3年的全剂量膀胱内BCG。在肿瘤进展风险最高的患者中，应考虑立即行根治性膀胱切除术（RC）。RC被推荐用于BCG难治性肿瘤。指南的长版可在EAU网站上获得（www。uroweb.org/guidelines)。
这些简化的EAU指南提供了有关NMIBC的诊断和治疗的最新信息，以纳入临床实践。
欧洲泌尿外科协会发布了关于非肌肉浸润性膀胱癌（NMIBC）的最新指南。将患者分层为低，中介-，高危人群对于辅助膀胱灌注的决定至关重要.风险表可用于估计复发和进展的风险。只有在滴注失败或进展风险最高的NMIBC中，才应考虑根治性膀胱切除术。
